Advancing science and implementing novel, cutting edge Technologies

StemBANCC aims to provide well characterised patient derived induced pluripotent stem cell lines and associated biomaterials in an accessible and sustainable bio-bank. StemBANCC also aims to demonstrate proof of concept for the utility of induced pluripotent stem cells in drug discovery for hard-to-treat disorders.

 

Hagedorn Research Institute

Department of Stem Cell Biology

Niels Steensens vej 6

DK-2820 Gentofte

 

novonordisk.com

 

Project leader

 
Dr. Mattias Hansson
 
Phone +45 4442 9137
Fax +45 4443 8000
E-Mail  

Project staff

 
Dr. Christian le Fèvre Honoré
 
Fax +45 4443 8000
E-Mail  

 

 
Dr. Nicolaj  Strøyer Christophersen   
 
Phone +45 4442 4047
Fax +45 4443 8000
E-Mail  

Institute presentation

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Hagedorn Research Institute (HRI) in Gentofte, Denmark is a fully integrated part of Novo Nordisk. Our vision is to find a cure for diabetes and its complications and to identify new opportunities for treating diabetes. Our core focus is the effort to identify new biology-based targets for potential drugs to feed Novo Nordisk’s pipeline within the key areas of diabetes pathogenesis, treatment and cure. The aim of the Stem Cell Biology department is to develop cell replacement therapy into a viable option for treating Diabetes Mellitus. The reconstitution of a functional beta cell mass can restore blood glucose homeostasis in diabetic patients and eliminates the need for insulin injections. Our main objective is to generate clinical-grade pancreatic beta cells from pluripotent stem cells by harnessing their differentiation potential and to recapitulate the complex process of beta cell formation in vitro.

 

Gurdon Institute
Tennis Court Road
Cambridge CB2 1QN

 

gurdon.cam.ac.uk

 

Project leader

 
Dr. Rick Livesey
Phone +44 1223 763281
Fax +44 1223 334089
E-Mail  

Institute presentation

The Institute, an integrated part of Cambridge University, was founded in 1989 to promote research in the areas of developmental biology and cancer biology.  The Institute hosts a number of independent research groups in a purpose-built building designed to promote as much interaction as possible.  Developmental and cancer biology are complementary since developmental biology is concerned with how cells, including stem cells, acquire and maintain their normal function, whereas cancer is a result of a cell breaking loose from its correct controls and becoming abnormal.  Both areas require a detailed knowledge of intra- and intercellular processes, which need to be analysed at the scientific and technical levels.  To understand what goes wrong when a cell becomes cancerous requires knowledge of the processes that ensure correct function in normal development. Professor Sir John Gurdon, a founder of the Institute, was awarded the Nobel Prize for Physiology or Medicine in 2012 "for the discovery that mature cells can be reprogrammed to become pluripotent".

 

Pharma Research and Early Development (pRED)
Grenzacherstrasse 124
CH-4070 Basel
Switzerland

 

roche.com

Project leader

 
Mr. Martin Graf
IMI StemBANCC Coordinator
Head of Stem Cell Platform
Discovery Technologies
E-Mail  

Project staff

 
Dr. Nicole Clemann
WP10 co-leader
Non Clinical Safety
E-Mail  

 

 
Dr. Mark Burcin
WP3 co-leader
Lab Leader, Stem Cell Platform
Discovery Technologies
E-Mail  

 

 
Mr. Klaus Christensen
WP03
Lab Leader, Stem Cell Platform
Discovery Technologies
E-Mail  

 

 
Dr. Ravi Jagasia
WP08 - CNS
Lab Leader, Neuroscience Discovery
E-Mail  

 

 
Dr. Hansruedi Loetscher
WP08 - CNS
Head Molecular Neuroscience
Neuroscience Discovery
E-Mail  

 

   
Dr. Anna-Lisa Gündner
WP08 - CNS
Post Doc, Neuroscience Discovery
E-Mail  

 

   
Dr. Roberto Iacone
WP09 - Diabetes
Group Leader, Cardiovascular & Metabolic Diseases
E-Mail  

 

 
Dr. Osele Ciampi

WP09 WP10 

Post Doc, Cardiovascular & Metabolic Diseases
E-Mail  

Institute presentation

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

 

Neuroscience Discovery

67061 Ludwigshafen

Knollstrasse

Germany

 

abbvie.com

 

Project leader

 
Prof. Georg C. Terstappen
 
Phone: +49 621 589 3245
Fax: +49 621 589 3232
E-Mail  

Project staff

 
Dr. Viktor Lakics
Work package: EFPIA Co-Leader WP8
Phone: +49 621 589 2245
Fax: +49 621 589 3232
E-Mail  

 

 
Roberta de Filipps
 
Phone:

+49 621 589 2705

Fax: +49 621 589 3232
E-Mail  

 

 
Dr. Margot H.M. Bakker
Work package: WP2 and WP11
Phone: +49 621 589 3191
Fax: +49 621 589 3232
E-Mail  

 

 
Dr. Eric Blomme
Work package: WP08 - CNS
Lab Leader, Neuroscience Discovery
Phone: +1 847 937 2269
Fax: +49 621 589 3232
E-Mail  

Institute presentation

AbbVie is a global, research-based biopharmaceutical company focused on developing advanced therapies that address some of the world’s most serious diseases. Our goal is to improve patients' health and quality of life – with innovative specialty medicines, focused research and groundbreaking initiatives for patients.

 

To make an impact on people's lives, we draw on our deep expertise in some of the most difficult-to-treat diseases and on our understanding of the patient journey to identify opportunities to create better outcomes at every stage.

 

Approximately 2400 AbbVie employees in Germany work to achieve that goal. We

are represented here at our head office in Wiesbaden and at our research and

manufacturing site in Ludwigshafen.

 

With our specialty drugs and biologics, we are a leader in many of the therapeutic areas in which we are involved. In Germany, these include rheumatic disease, psoriasis, chronic inflammatory bowel disease, HIV/AIDS, RSV infection in preterm babies, Parkinson's disease, kidney disease and anaesthesiology.

 

Our discovery and development efforts are focused on a core set of therapeutic areas where we have proven expertise and where we believe we can have an even greater impact on the disease and how it is managed. These core areas of focus include hepatitis C (HCV), neuroscience, immunology, oncology, renal disease, and women's health.

 

In the area of neuroscience, we are conducting innovative research on compounds that target receptors in the brain, which help regulate pain, mood, memory and other neurological functions. We have a number of early and advanced investigational compounds in human studies for conditions such as schizophrenia, chronic pain, Alzheimer's disease, Parkinson's disease, and multiple sclerosis (MS) - all of which affect millions of people worldwide.

 

Partnerships play a key role for us. We know how important collaborative R&D agreements and partnerships are to speed up medical breakthroughs. To find potential new therapies for patients we look both inside and outside AbbVie to help uncover promising discoveries. We partner and collaborate with peer companies, universities, non-governmental organizations, and others to help find solutions for patients around the globe. At AbbVie, we understand there are times when we can accomplish more together than alone.

 

For more information visit abbvie.com

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.
Ok Decline